Abstract:Chromogenic in situ hybridization (CISH) has shown the potential to replace fluorescence in situ hybridization (FISH) to determine HER2 gene status. To validate the reliability of CISH, we used 226 consecutive breast carcinomas from 2 institutions and tested CISH and FISH on the same tumor set simultaneously at different test sites. Besides manufacturers’ scoring criteria, the new American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines were used to interpret HER2 status. The concordance between CISH and FISH for positive and negative results was 98.5% at site A and 98.6% at site B using the manufacturers’ criteria, and 99.0% at site A and 99.1% at site B using the ASCO/CAP criteria. Reproducibility of CISH results was more than 98.0% among 3 sites using the manufacturers’ criteria and 100.0% between 2 sites using the ASCO/CAP criteria. Our results confirm that CISH is reliable for HER2 testing per ASCO/CAP guidelines. Identification of human epidermal growth factor receptor 2 (HER2) status is important to making therapeutic decisions for patients with breast cancer, both at the time of initial diagnosis and at recurrence. Positive HER2 status (ie, overexpression of the HER2 protein or amplification of the HER2 gene) has been reported in approximately 15% to 20% of women with newly diagnosed breast cancers1,2 and is associated with a poor clinical outcome, resistance to hormone therapy, and resistance to certain types of chemotherapy.3-7 More important, positive HER2 status is a strong predictor of response to anti-HER2 therapies, such as trastuzumab (Herceptin), and, therefore, is a major criterion for patient selection for HER2-targeted therapies.8-15 However, trastuzumab therapy is expensive16 and associated with rare but severe cardiotoxic effects.8,15,17,18 Accurate HER2 testing allows oncologists to administer timely anti-HER2 therapy to patients who may benefit and to spare patients who would not benefit from the costly and potentially harmful regimen. Various methods of assessing gene amplification, messenger RNA level, and protein expression have been used to determine HER2 status in breast cancer, including Southern, Northern, and Western blots; polymerase chain reaction; and enzyme-linked immunosorbent assay. Immunohistochemical analysis and fluorescence in situ hybridization (FISH) are the 2 methods most widely used to determine HER2 status in the routine diagnostic setting. Each method has advantages and disadvantages. Immunohistochemical analysis measures HER2 protein expression on the cell surface and is easy to conduct in most pathology laboratories. However, the result of immunohistochemical staining is relatively susceptible to variations in tissue fixation and processing. Approximately 20% of HER2 protein tests performed in the local pathology

Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations.

Chromogenic in Situ Hybridization is a Reliable Method for DetectingHER2Gene Status in Breast Cancer

Comparision of HER2/neu Oncogene Detected by Chromogenic In-Situ Hybridization and Immunohistochemistry in Breast Cancer

Determination of HER2 Gene Amplification by Chromogenic in Situ Hybridization (CISH) in Archival Breast Carcinoma.

[Analysis of HER2 Gene Amplification and Its Protein Expression in 165 Cases of Breast Carcinoma: Comparison of Chromogenic In-Situ Hybridization and Immunohistochemistry].

Comparison between analysis of HER2 gene and chromosome 17 in breast cancer by dual-probe chromogenic in situ hybridization and fluorescence in situ hybridization

HER2 Gene Amplification by Fluorescence In Situ Hybridization (FISH) Compared With Immunohistochemistry (IHC) in 122 Equivocal Gastric Cancer Cases.

[Assessment of HER2 Gene Amplification in Breast Cancer: a Comparison of Dual-Color In-Situ Hybridization and Fluorescence In-Situ Hybridization].

Impact of the 2018 ASCO/CAP HER2 Guidelines Update for HER2 Testing by FISH in Breast Cancer

FISH Still a Very Important Tool to Monitor Breast Cancer: Review of Recent Literature, Alternative Methods, and Proposed Techniques

Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections

Re-evaluation of HER2 status in 1 501 invasive breast cancers according to the 2013 American Society of Clinical Oncology/College of American Pathologist guidelines

Putting the colours into chromogenic in situ hybridization (CISH)

Semi-automated analysis of HER2 immunohistochemistry in invasive breast carcinoma using whole slide images: utility for interpretation in clinical practice

Concordance between pathologists and between specimen types in detection of HER2-low breast carcinoma by immunohistochemistry

HER2 Status in Gastric and Gastroesophageal Junction Cancer Assessed by Local and Central Laboratories: Chinese Results of the HER-EAGLE Study.

Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP Recommendations

HER2 Overexpression/amplification Status in Colorectal Cancer: a Comparison Between Immunohistochemistry and Fluorescence in Situ Hybridization Using Five Different Immunohistochemical Scoring Criteria

Consistency of HER-2 Expression Detected by Both Immunohistochemistry and Fluorescence in Situ Hybridization in Gastric Cancer

Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients

Performance of HER2 DAKO HercepTest and Ventana 4B5 Immunohistochemical Assays on Detecting HER2 Gene-Amplification in Uterine Serous Carcinomas